Prostate and other male cancers:

Indications for: Leuprolide acetate

Palliative treatment of advanced prostatic carcinoma.

Adult Dosage:

1mg SC daily. Rotate inj site.

Children Dosage:

Not applicable.

Leuprolide acetate Contraindications:

Women. Pregnancy (Cat.X).

Leuprolide acetate Warnings/Precautions:

Metastatic vertebral lesions. Urinary obstruction. Monitor serum testosterone, PSA, acid phosphatase. Increased risk of diabetes, MI, sudden cardiac death, stroke; monitor blood glucose, HbA1c, and for signs/symptoms of CVD during therapy. Risk of QT prolongation: long-term androgen deprivation therapy, congenital long QT syndrome, electrolyte abnormalities, or CHF, and concomitant Class IA or III antiarrhythmics. Instruct patient on correct self administration.

Leuprolide acetate Classification:

GnRH analogue.

Leuprolide acetate Interactions:

Concomitant Class IA (eg, quinidine, procainamide) or Class III (eg, amiodarone, sotalol) antiarrhythmics may prolong the QT interval.

Adverse Reactions:

Hot flashes/sweats, inj site reaction, initial worsening of signs/symptoms (eg, bone pain, urinary tract obstruction, hematuria), edema, GI upset, pain, cardiovascular events, CNS and antiandrogenic effects, asthenia, spinal cord compression; hyperglycemia, anaphylactoid, photosensitivity.

Drug Elimination:

Half-life: ~3 hours.

How Supplied:

Contact supplier